Cell & Gene Therapy Manufacturing: Considerations For Early-Stage Companies

▤ Summary

This article explains how cell and gene therapy developers are shifting from building internal manufacturing toward using external partners and local cleanroom providers. It argues that early-stage companies should choose CDMOs based on capability, not geography, especially when products can be cryogenically stored and shipped. The piece also highlights the high cost of GMP facilities and the importance of global approvals to improve patient access and reduce unit manufacturing costs. It concludes that broader partnerships and better regulatory alignment will help advanced medicines reach more patients worldwide.

▦ Linked Companies